Inactive Instrument

Vifor Pharma

Equities

VIFN

CH0364749348

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis CI
Court Cancels Public Shares of Vifor Pharma after Merger with CSL MT
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand MT
Australia's CSL raises annual profit forecast on Swiss acquisition RE
Global markets live: Darktrace, Intel, Twitter, Meta, Uber... Our Logo
Vifor Pharma Gets Approval To Delist From Swiss Bourse MT
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease MT
Fitch Pulls Vifor Pharma's Rating After CSL Takeover MT
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU MT
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease MT
Australia biotech giant CSL reports profit dip, flags cost spiral RE
Global markets live: Walt Disney, Bank of America, Sonos, ABB, Roche... Our Logo
Australia's CSL Closes Vifor Pharma Purchase MT
CSL Completes Vifor Pharma Acquisition MT
CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders. CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P Global BMI Index CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350 - Health Care CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350 CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P Global 1200 CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P International 700 CI
Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index CI
Vifor Pharma Announces Resignation of Abbas Hussain as CEO CI
CSL Receives All Regulatory Approvals for Vifor Pharma Acquisition MT
Chart Vifor Pharma
More charts
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.
More about the company
  1. Stock
  2. Equities
  3. Stock Vifor Pharma - Swiss Exchange
  4. News Vifor Pharma
  5. AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation